الفهرس 
IntroductionOnly 14 pages are availabe for public view
 |  | from | 138 |  |  |
| | | from | 138 | | |
Abstract
The coronavirus disease 2019 (COVID-19) is a new coronavirus that causes
severe respiratory disease. Because immunological status is critical in battling
coronavirus, herbal medications with immunomodulatory properties may help to
treat COVID-19. Nigella Sativa is herbal medication with antiviral and
immunomodulatory properties, and its therapeutic efficacy suggests that it might be
used as an adjuvant therapy in COVID-19. Furthermore, Vitamin D3 possesses
immunomodulatory properties, however the therapeutic effect of Vitamin D3
supplementation in SARS-CoV-2 infection is unclear.
The study aimed to investigate the effect of Nigella Sativa and Vitamin D3 as
single supplemental therapy and in a combination as an antiviral therapy. The
clinical effect is assessed by negative polymerase chain reaction and symptoms
relief over the course of 14 days. The design was an open-label randomized
controlled clinical trial, and conducted at the Respiratory Hospital at the Kobry El
Qobba Armed Forces Medical Complex.
Hundred and twenty COVID-19 patients with mild to moderate symptoms were
included in the study. They were randomly assigned in to four groups, thirty patients
each, as follows;
-group 1 received an oral dose of 900 mg Nigella Sativa 450 mg soft gelatin
capsules twice daily for two weeks,
-group 2 received 2000 IU of Vitamin D3 1000 IU tablets given as two tablets once
daily,
-group 3 received 900 mg of Nigella Sativa and 2000 IU of Vitamin D3 in the same
manner of dosing as in the previous groups,
Summary
MSc Thesis 2023 Page 88
-group 4 who are the controls. All groups received standard therapy for COVID- 19
infections for clinical management of COVID-19 clinical symptoms.
Study results indicated that Nigella Sativa - Vitamin D3 combination added to the
standard therapy of COVID-19 infections significantly contributed to the alleviation
of most COVID-19 disease’ signs and symptoms.
The results showed that 50% of patients were free of cough after 7 days, 70%
showed an absence of fatigue after 4 days, 80% showed no headache after 5 days,
while, 90% were free of rhinorrhea after 7 days and 86.7% of the patients had no
dyspnea after 7 days.
Furthermore, patients in all groups showed a reduced median temperature after 3
days of treatment. Polymerase chain reaction (PCR) test recorded negative results
on the seventh and fourteenth day of therapy were superior in the Nigella Sativa -
Vitamin D3 combination group compared to the other studied groups.
The results of this study showed a promising therapeutic benefit of the
administration of Nigella Sativa and Vitamin D3 combination in COVID-19 patients
with mild to moderate symptoms. Additionally, the remarkable viral clearance in a
short time interval and reduction in the severity and progression of symptoms
recommended the use of this combination as an add-on therapy for the management
of COVID-19 patients.